CR20170078A - Formulaciones en compromido de la (4-trifluorometilfenil)amida del acido (z)-2-ciano-3-hidroxibutil-2-enoico con estabilidad mejorada - Google Patents

Formulaciones en compromido de la (4-trifluorometilfenil)amida del acido (z)-2-ciano-3-hidroxibutil-2-enoico con estabilidad mejorada

Info

Publication number
CR20170078A
CR20170078A CR20170078A CR20170078A CR20170078A CR 20170078 A CR20170078 A CR 20170078A CR 20170078 A CR20170078 A CR 20170078A CR 20170078 A CR20170078 A CR 20170078A CR 20170078 A CR20170078 A CR 20170078A
Authority
CR
Costa Rica
Prior art keywords
trifluorometilfenil
hydroxibute
enoico
ciano
amida
Prior art date
Application number
CR20170078A
Other languages
English (en)
Inventor
Gerrit Hauck
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41510564&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR20170078(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of CR20170078A publication Critical patent/CR20170078A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/32—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
    • C07C255/42—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being further bound to other hetero atoms
    • C07C255/44—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being further bound to other hetero atoms at least one of the singly-bound nitrogen atoms being acylated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Neurosurgery (AREA)
  • Otolaryngology (AREA)
  • Nutrition Science (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La invención se refiere a composiciones farmacéuticas sólidas que comprenden la (4¿-trifluorometilfenil)amida del ácido (Z)-2-ciano-3-hidroxibut-2-enoico, así como a procesos para su preparación, a métodos para utilizar dichas composiciones para tratar sujetos que padecen enfermedades autoinmunológicas, en particular lupus eritematoso sistémico o enfermedad del injerto frente al receptor crónica, esclerosis múltiple o artritis reumatoide.
CR20170078A 2009-09-18 2010-09-14 Formulaciones en compromido de la (4-trifluorometilfenil)amida del acido (z)-2-ciano-3-hidroxibutil-2-enoico con estabilidad mejorada CR20170078A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09290716 2009-09-18
PCT/EP2010/063439 WO2011032929A1 (en) 2009-09-18 2010-09-14 (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluormethylphenyl)-amide tablet formulations with improved stability

Publications (1)

Publication Number Publication Date
CR20170078A true CR20170078A (es) 2017-05-22

Family

ID=41510564

Family Applications (2)

Application Number Title Priority Date Filing Date
CR20170078A CR20170078A (es) 2009-09-18 2010-09-14 Formulaciones en compromido de la (4-trifluorometilfenil)amida del acido (z)-2-ciano-3-hidroxibutil-2-enoico con estabilidad mejorada
CR20120116A CR20120116A (es) 2009-09-18 2012-03-12 Formulaciones en comprimido de la (4-trifluorometilfenil) amida del acido (z)-2-ciano-3-hidroxibutil -2-enoico con estabilidad mejorada

Family Applications After (1)

Application Number Title Priority Date Filing Date
CR20120116A CR20120116A (es) 2009-09-18 2012-03-12 Formulaciones en comprimido de la (4-trifluorometilfenil) amida del acido (z)-2-ciano-3-hidroxibutil -2-enoico con estabilidad mejorada

Country Status (40)

Country Link
US (5) US20120172427A1 (es)
EP (1) EP2477611B1 (es)
JP (1) JP2013505213A (es)
KR (1) KR101547880B1 (es)
CN (4) CN104739821B (es)
AR (1) AR078383A1 (es)
AU (2) AU2010297357B2 (es)
BR (1) BR112012006184B1 (es)
CA (1) CA2772275A1 (es)
CL (1) CL2015000047A1 (es)
CO (1) CO6511244A2 (es)
CR (2) CR20170078A (es)
CY (1) CY1119364T1 (es)
DK (1) DK2477611T3 (es)
DO (1) DOP2012000070A (es)
ES (1) ES2625731T3 (es)
GT (1) GT201200075A (es)
HK (2) HK1206244A1 (es)
HN (1) HN2012000576A (es)
HR (1) HRP20170904T1 (es)
HU (1) HUE032963T2 (es)
IL (3) IL218492A (es)
JO (1) JO3327B1 (es)
LT (1) LT2477611T (es)
MA (1) MA33585B1 (es)
ME (1) ME02765B (es)
MX (1) MX336663B (es)
MY (1) MY155613A (es)
NZ (2) NZ617025A (es)
PE (2) PE20121478A1 (es)
PL (1) PL2477611T3 (es)
PT (1) PT2477611T (es)
RS (1) RS56074B1 (es)
RU (2) RU2012115459A (es)
SI (1) SI2477611T1 (es)
TN (1) TN2012000061A1 (es)
TW (2) TWI522130B (es)
UA (2) UA107582C2 (es)
UY (1) UY32889A (es)
WO (1) WO2011032929A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2477611T3 (en) * 2009-09-18 2017-07-10 Sanofi Sa (Z) -2-CYANO-3-HYDROXYBUT-2-ENIC ACID (4'-TRIFLUORMETHYLPHENYL) AMID TABLE FORMULATIONS WITH IMPROVED STABILITY
RU2493845C1 (ru) * 2012-06-07 2013-09-27 Общество с ограниченной ответственностью "ВАЛЕНТА ИНТЕЛЛЕКТ" Композиция для лечения рассеянного склероза (варианты)
KR20160079123A (ko) * 2013-11-22 2016-07-05 젠자임 코포레이션 신경변성 질병을 치료하기 위한 신규한 방법
CN103656657A (zh) * 2013-12-18 2014-03-26 北京科源创欣科技有限公司 特立氟胺药物组合物及制备方法
SI3122358T1 (sl) 2014-03-26 2021-04-30 Astex Therapeutics Ltd. Kombinacije FGFR- in CMET-inhibitorjev za zdravljenje raka
US20160058730A1 (en) * 2014-08-29 2016-03-03 Cadila Healthcare Limited Pharmaceutical compositions of teriflunomide
WO2016079687A1 (en) * 2014-11-18 2016-05-26 Lupin Limited Oral pharmaceutical composition of teriflunomide
JOP20200201A1 (ar) 2015-02-10 2017-06-16 Astex Therapeutics Ltd تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين
WO2016189406A1 (en) 2015-05-23 2016-12-01 Ftf Pharma Private Limited Pharmaceutical composition of teriflunomide
CA2996632C (en) 2015-09-01 2023-10-17 Bayer Pharma Aktiengesellschaft Compounds and methods useful for treating or preventing hematological cancers
WO2017037645A1 (en) * 2015-09-02 2017-03-09 Leiutis Pharmaceuticals Pvt Ltd Stable pharmaceutical formulations of teriflunomide
WO2017056104A1 (en) * 2015-09-28 2017-04-06 Natco Pharma Limited Stable pharmaceutical compositions of teriflunomide
WO2017125841A1 (en) * 2016-01-20 2017-07-27 Emcure Pharmaceuticals Limited Pharmaceutical compositions of teriflunomide
JOP20190207A1 (ar) 2017-03-14 2019-09-10 Actelion Pharmaceuticals Ltd تركيبة صيدلانية تشتمل على بونيسيمود
DK3999038T3 (da) * 2019-07-17 2024-03-18 Cytokinetics Inc Orale formuleringer af en kardial sarcomer-inhibitor
WO2022085015A1 (en) * 2020-10-24 2022-04-28 V-Ensure Pharma Technologies Private Limited A solid oral composition of teriflunomide
GR1010137B (el) 2020-12-15 2021-12-07 Φαρματεν Α.Β.Ε.Ε., Στερεη φαρμακοτεχνικη μορφη αμεσης αποδεσμευσης περιεχουσα τεριφλουνομιδη και μεθοδος παρασκευης αυτης
TR202022336A2 (tr) * 2020-12-30 2022-07-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi A film coated tablet comprising teriflunomide
EP4382097A1 (en) 2022-11-25 2024-06-12 Sanovel Ilac Sanayi Ve Ticaret A.S. A tablet comprising teriflunomide
WO2024112298A1 (en) * 2022-11-25 2024-05-30 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi A tablet comprising teriflunomide

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3852294A (en) * 1968-08-27 1974-12-03 Merck Patent Gmbh Bis-quaternary pyridinium salts
US5268382A (en) 1985-09-27 1993-12-07 Hoechst Aktiengesellschaft Medicaments to combat autoimmune diseases, in particular systemic lupus erythematosus
DE3534440A1 (de) 1985-09-27 1987-04-02 Hoechst Ag Arzneimittel gegen chronische graft-versus-host-krankheiten sowie gegen autoimmunerkrankungen, insbesondere systemischen lupus erythematodes
US6133301A (en) 1991-08-22 2000-10-17 Aventis Pharma Deutschland Gmbh Pharmaceuticals for the treatment of rejection reactions in organ transplantations
US5700823A (en) 1994-01-07 1997-12-23 Sugen, Inc. Treatment of platelet derived growth factor related disorders such as cancers
GB9408117D0 (en) * 1994-04-23 1994-06-15 Smithkline Beecham Corp Pharmaceutical formulations
ES2148561T3 (es) 1994-10-17 2000-10-16 Aventis Pharma Ltd Prevencion y curacion de enfermedades alergicas de tipo i.
DK0987256T3 (da) 1997-08-08 2002-02-11 Aventis Pharma Gmbh Krystalform af N-(4-trifluormethylphenyl)-5-methylisoxazol-4-carboxylsyreamid
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
WO2001060363A1 (en) 2000-02-15 2001-08-23 Teva Pharmaceutical Industries Ltd. A method for synthesizing leflunomide
GB0123571D0 (en) * 2001-04-05 2001-11-21 Aventis Pharm Prod Inc Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating multiple sclerosis
SI1381356T1 (sl) 2001-04-05 2008-12-31 Aventis Pharma Inc Uporaba (Z)-2-ciano-3-hidroksi-but-2-enojska kislina-(4'-trifluorometilfenil)-amida za zdravljenje multiple skleroze
US20050158371A1 (en) 2002-02-12 2005-07-21 Sumitomo Pharmaceuticals Co., Ltd. Novel external agent
AU2004270174B2 (en) * 2003-08-29 2010-05-20 Transform Pharmaceuticals, Inc. Pharmaceutical compositions and method of using levodopa and carbidopa
GB2394660A (en) 2003-12-17 2004-05-05 Niche Generics Ltd Stabilisation of pharmaceutical compositions comprising ACE inhibitor by absence of acidic excipients having large specific surface area, eg silicon dioxide
US20050220874A1 (en) * 2004-04-02 2005-10-06 Chien-Hsuan Han Pharmaceutical dosage forms having immediate release and controlled release properties that contain a GABAB receptor agonist
US20060024376A1 (en) * 2004-07-30 2006-02-02 The University Of Chicago Methods and compositions for reducing toxicity associated with leflunomide treatment
EP1804782A1 (en) * 2004-10-19 2007-07-11 Aventis Pharmaceuticals Inc. Use of (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating inflammatory bowel disease
TWI275029B (en) * 2005-11-18 2007-03-01 Hon Hai Prec Ind Co Ltd An embedded system and method for processing data thereof
CN101360493A (zh) 2006-01-24 2009-02-04 特瓦制药工业有限公司 左乙拉西坦制剂和制备方法
DE102006017896A1 (de) * 2006-04-13 2007-10-25 Tiefenbacher Pharmachemikalien Alfred E. Tiefenbacher Gmbh & Co. Kg Leflunomid enthaltende pharmazeutische Zusammensetzungen
EP1990048A3 (en) 2007-05-08 2009-05-06 Ulrike Wiebelitz Therapy of benign prostatic hyperplasia (bph)
DK2477611T3 (en) * 2009-09-18 2017-07-10 Sanofi Sa (Z) -2-CYANO-3-HYDROXYBUT-2-ENIC ACID (4'-TRIFLUORMETHYLPHENYL) AMID TABLE FORMULATIONS WITH IMPROVED STABILITY
EP2762135A1 (en) * 2013-02-04 2014-08-06 Sanofi Methods for reducing the risk of an adverse teriflunomide and rosuvastatin interaction in multiple sclerosis patients

Also Published As

Publication number Publication date
ME02765B (me) 2018-01-20
HN2012000576A (es) 2015-01-26
IL264912B (en) 2019-11-28
PT2477611T (pt) 2017-06-05
MX2012003122A (es) 2012-04-10
US20140235888A1 (en) 2014-08-21
AU2013257516B2 (en) 2015-09-17
CO6511244A2 (es) 2012-08-31
KR20120089461A (ko) 2012-08-10
US8802735B2 (en) 2014-08-12
NZ598744A (en) 2013-11-29
ES2625731T3 (es) 2017-07-20
CA2772275A1 (en) 2011-03-24
TN2012000061A1 (en) 2013-09-19
LT2477611T (lt) 2017-06-26
HK1206245A1 (en) 2016-01-08
IL218492A (en) 2016-04-21
CR20120116A (es) 2012-06-15
JP2013505213A (ja) 2013-02-14
AU2010297357A1 (en) 2012-04-05
DK2477611T3 (en) 2017-07-10
PE20152031A1 (es) 2016-01-14
US20170247319A1 (en) 2017-08-31
RU2681079C2 (ru) 2019-03-04
MX336663B (es) 2016-01-27
MY155613A (en) 2015-11-13
IL244809B (en) 2019-03-31
EP2477611A1 (en) 2012-07-25
UY32889A (es) 2011-04-29
RS56074B1 (sr) 2017-10-31
CN104666238A (zh) 2015-06-03
CN104739821A (zh) 2015-07-01
DOP2012000070A (es) 2012-05-31
GT201200075A (es) 2014-05-14
US20120172427A1 (en) 2012-07-05
EP2477611B1 (en) 2017-04-05
BR112012006184B1 (pt) 2022-10-18
CN102596184A (zh) 2012-07-18
JO3327B1 (ar) 2019-03-13
IL244809A0 (en) 2016-04-21
RU2015151938A3 (es) 2019-01-15
CY1119364T1 (el) 2018-02-14
IL218492A0 (en) 2012-04-30
WO2011032929A1 (en) 2011-03-24
UA107582C2 (uk) 2015-01-26
CN104739821B (zh) 2018-04-06
AU2010297357B2 (en) 2013-11-07
CL2015000047A1 (es) 2015-06-12
UA115979C2 (uk) 2018-01-25
CN104666272A (zh) 2015-06-03
NZ617025A (en) 2014-03-28
PL2477611T3 (pl) 2017-09-29
RU2012115459A (ru) 2013-10-27
TWI522130B (zh) 2016-02-21
TW201517935A (zh) 2015-05-16
TWI468190B (zh) 2015-01-11
KR101547880B1 (ko) 2015-08-27
US20190241505A1 (en) 2019-08-08
RU2015151938A (ru) 2019-01-15
PE20121478A1 (es) 2012-11-12
HUE032963T2 (en) 2017-11-28
CN102596184B (zh) 2015-03-11
MA33585B1 (fr) 2012-09-01
AR078383A1 (es) 2011-11-02
TW201117838A (en) 2011-06-01
HK1206244A1 (en) 2016-01-08
HRP20170904T1 (hr) 2017-09-08
SI2477611T1 (sl) 2017-07-31
BR112012006184A2 (pt) 2016-05-31
US20120208880A1 (en) 2012-08-16
CN104666238B (zh) 2018-04-06

Similar Documents

Publication Publication Date Title
CR20170078A (es) Formulaciones en compromido de la (4-trifluorometilfenil)amida del acido (z)-2-ciano-3-hidroxibutil-2-enoico con estabilidad mejorada
ECSP11010932A (es) Compuestos de azaindazol como antagonistas del receptor de ccr1
CL2011002745A1 (es) Compuestos derivados de acidos grasos poliinsaturados; metodo de preparacion; composicion farmaceutica que los comprende; y su uso para la prevencion o el tratamiento de trastornos cardiovasculares, metabolicos e inflamatorios, tales como, artritis reumatoide, aterosclerosis, diabetes, dislipidemia, entre otras.
BRPI1014956B8 (pt) agentes anti-inflamatórios
TW201129381A (en) Antibodies against human CSF-1R and uses thereof
MY161773A (en) Amylin analogues and pharmaceutical compositions thereof
BRPI1009315B8 (pt) composto anti-flamatórios e suas composições farmacêuticas
BR112014009031A2 (pt) formulações de etanercept estabilizadas com íons de metais
BR112014014809A2 (pt) composições farmacêuticas compreendendo glitazonas e ativadores de nrf2
BRPI0909040B8 (pt) derivados de azetidina e ciclobutano, seus usos, e composição
BR112017022008A2 (pt) composições de di-hidropiridoisoquinolinonas e composições farmacêuticas das mesmas para o tratamento de transtornos inflamatórios
CL2013001101A1 (es) Compuestos derivados de rasagilina enriquecida con deuterio; su proceso de preparacion; mezcla de al menos dos compuestos enriquecidos con deuterio; composicion farmaceutica que los comprende, util para tratar un trastorno neurodegenerativo tal como mal de parkinson, sindrome de piernas inquietas, perdida auditiva y disfuncion olfativa.
MY173372A (en) Polyethylene glycol based prodrug of adrenomedullin and use thereof
MX2014000142A (es) Uso de anticuerpos agonistas anti-cd83 para tratar enfermedades autoinmunes.
WO2012103360A3 (en) Wnt compositions and methods of use thereof
CL2008003802A1 (es) Compuestos derivados de tioeteres c-21, agonistas del receptor de glucocorticoide; composicion farmaceutica; y uso para el tratamiento o profilaxis de una enfermedad o afeccion inmune, autoinmune o inflamatoria, tales como artritis reumatoide y esclerosis multiple.
BR112012024232A8 (pt) "aptâmero de 73 nucleotídeos ou menos, complexo, composição farmacêutica e medicamento anti-dor"
NI201200041A (es) Formulaciones en comprimido de la (4' - trifluorometilfenil) amida del ácido (z) - 2 - ciano - 3 - hidroxibut - 2 - enoico con estabilidad mejorada
SG10201803880TA (en) Stable compositions of neuroactive peptides
GB201206761D0 (en) Anti-atherogenic peptides
WO2011094389A3 (en) Cxcr4 antagonists for imaging of cancer and inflammatory disorders
CL2012000101A1 (es) Compuestos derivados de piridina, agonistas del receptor s1p1/edg1;composicion farmaceutica; uso del compuesto para el tratamiento de enfermedades o trastornos asociados con el sistema inmune activado tales como rechazo de organos, sindromes autoinmunes que incluyen artritis reumatoide, entre otras.
CL2011000623A1 (es) Celula a la que se le ha incorporado un aminoacido no natural p-acetil-feninilalanina en la secuencia de aminoacidos de un producto genico esencial; celula de e.coli a la que se le ha incorporado un aminoacido no natural en un producto genico esencial. composiciones y usos.
TR201106224A2 (tr) Solunum yolu hastalıkları tedavisinde kullanılan farmasötik bileşimler.
UA111139C2 (uk) Тверді фармацевтичні композиції і способи їхнього отримання